A generic version of Xarelto (rivaroxaban) is not yet available in the United States [1]. The drug's patent exclusivity is a key factor in the absence of generic competition [2].
When does Xarelto's patent expire?
The primary patents protecting Xarelto are set to expire in 2028 [2]. However, various legal challenges and other patents could influence the actual market entry of generic versions [3].
Why are companies challenging Xarelto's patents?
Companies seeking to market generic versions often challenge existing patents. These challenges can involve arguing that the patents are invalid or that their own products do not infringe upon them. Such legal actions are common in the pharmaceutical industry as generics manufacturers aim to bring more affordable alternatives to market sooner [4].
How do generic drugs become available?
For a generic drug to become available, the patents covering the brand-name drug must expire or be successfully challenged. Once exclusivity ends, the U.S. Food and Drug Administration (FDA) can approve generic versions that are demonstrated to be bioequivalent to the brand-name drug [1][5].
What are the alternatives to Xarelto?
Xarelto is a blood thinner used to prevent and treat blood clots. Other anticoagulant medications are available, including other direct oral anticoagulants (DOACs) like Eliquis (apixaban) and Pradaxa (dabigatran), as well as warfarin, which has been in use for a longer time [6]. The choice of anticoagulant depends on individual patient factors and medical conditions [7].
Sources:
[1] https://www.drugs.com/availability/generic-xarelto.html
[2] https://drugpatentwatch.com/drug/xarelto
[3] https://www.law360.com/articles/1309391/xarelto-patent-battle-heats-up-in-del
[4] https://www.reuters.com/legal/transactional/bayer-j-and-j-lose-bid-bar-generic-rivaroxaban-challenge-2023-11-17/
[5] https://www.fda.gov/drugs/generic-drugs/what-you-need-know-about-generic-drugs
[6] https://www.xarelto.com/hcp/how-xarelto-works/comparison-to-other-anticoagulants
[7] https://www.uptodate.com/contents/overview-of-the-management-of-atrial-fibrillation-stroke-risk-and-bleeding-risk